1
|
Ferreira M, Freitas-Silva M, Assis J, Pinto R, Nunes JP, Medeiros R. The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics 2020; 21:125-140. [PMID: 31957546 DOI: 10.2217/pgs-2019-0133] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Despite the clinical benefits of aspirin, the interindividual variation in response to this antiplatelet drug is considerable. The manifestation of aspirin resistance (AR) is frequently observed, although this complex process remains poorly understood. While AR etiology is likely to be multifactorial, genetic factors appear to be preponderant. According to several genetic association studies, both genome-wide and candidate gene studies, numerous SNPs in cyclooxygenase, thromboxane and platelet receptors-related genes have been identified as capable of negatively affecting aspirin action. Thus, it is essential to understand the clinical relevance of AR-related SNPs as potential predictive and prognostic biomarkers as they may be essential to defining the AR phenotype.
Collapse
Affiliation(s)
- Márcia Ferreira
- Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de Almeida, 4200-4072 Porto, Portugal.,ICBAS, Abel Salazar Institute for the Biomedical Sciences, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
| | - Margarida Freitas-Silva
- FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 Porto, Portugal
| | - Joana Assis
- Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de Almeida, 4200-4072 Porto, Portugal.,FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 Porto, Portugal
| | - Ricardo Pinto
- Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de Almeida, 4200-4072 Porto, Portugal
| | - José P Nunes
- FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 Porto, Portugal
| | - Rui Medeiros
- Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de Almeida, 4200-4072 Porto, Portugal.,FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 Porto, Portugal.,Biomedical Research Center, Faculty of Health Sciences, Fernando Pessoa University, Praça 9 de Abril, 349, 4249-004 Porto, Portugal.,Department of Research, Portuguese League Against Cancer (NRNorte), Estrada Interior da Circunvalação, 6657, 4200-172 Porto, Portugal
| |
Collapse
|
2
|
Doly JS, Lorian E, Desormais I, Constans J, Bura Rivière A, Lacroix P. [Prevalence and prognosis of aspirin resistance in critical limb ischemia patients]. ACTA ACUST UNITED AC 2016; 41:358-364. [PMID: 27745943 DOI: 10.1016/j.jmv.2016.08.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 07/29/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To assess the prevalence and the association between aspirin resistance in critical limb ischemia patients using the VerifyNow® bed-side platelet test, and occurrence of cardiovascular morbidity and/or death at one year. MATERIALS AND METHODS National multicenter prospective observational study related to COPART II centers. From 2010 through 2014, 64 subjects hospitalized for critical limb ischemia and already treated by aspirin before the VerifyNow® test were included. A VerifyNow® test>550 ARU was defined as aspirin resistance. Critical limb ischemia was defined according to the TASC I criteria. The primary outcome was a composite including death, acute coronary syndrome, stroke and major amputation during the one-year follow-up period. RESULTS In all, 9/64 patients were aspirin resistant, the status was confirmed in one case. The prevalence of aspirin resistance was 14.06%. There was no significant difference between aspirin resistant and aspirin non-resistant groups in terms of cardiovascular history and glycemia status. Neither was there significant difference between the two groups in terms of survival. CONCLUSION Aspirin resistance was not predictive of poorer survival in critical limb ischemia patients. However, our population was limited. Considering that a clear definition of aspirin resistance and standardized diagnostic tests are lacking, complementary studies might be useful.
Collapse
Affiliation(s)
- J-S Doly
- Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
| | - E Lorian
- Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - I Desormais
- Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - J Constans
- Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - A Bura Rivière
- Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - P Lacroix
- Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France
| |
Collapse
|
3
|
Geraldo RB, Sathler PC, Lourenço AL, Saito MS, Cabral LM, Rampelotto PH, Castro HC. Platelets: still a therapeutical target for haemostatic disorders. Int J Mol Sci 2014; 15:17901-19. [PMID: 25295482 PMCID: PMC4227196 DOI: 10.3390/ijms151017901] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 08/26/2014] [Accepted: 09/23/2014] [Indexed: 11/16/2022] Open
Abstract
Platelets are cytoplasmatic fragments from bone marrow megakaryocytes present in blood. In this work, we review the basis of platelet mechanisms, their participation in syndromes and in arterial thrombosis, and their potential as a target for designing new antithrombotic agents. The option of new biotechnological sources is also explored.
Collapse
Affiliation(s)
- Reinaldo Barros Geraldo
- Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense (UFF), Niterói CEP 24210-130, RJ, Brazil.
| | - Plínio Cunha Sathler
- Programa de Pós-graduação em Patologia, Departamento de Patologia, Hospital Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), Niterói CEP 24030-215, RJ, Brazil.
| | - André Luiz Lourenço
- Programa de Pós-graduação em Patologia, Departamento de Patologia, Hospital Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), Niterói CEP 24030-215, RJ, Brazil.
| | - Max Seidy Saito
- Programa de Pós-graduação em Patologia, Departamento de Patologia, Hospital Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), Niterói CEP 24030-215, RJ, Brazil.
| | - Lucio M Cabral
- LabTIF, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro CEP 21941-590, RJ, Brazil.
| | - Pabulo Henrique Rampelotto
- Interdisciplinary Center for Biotechnology Research, Federal University of Pampa, Antônio Trilha Avenue, P.O. Box 1847, São Gabriel/RS 97300-000, Brazil.
| | - Helena Carla Castro
- Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense (UFF), Niterói CEP 24210-130, RJ, Brazil.
| |
Collapse
|